<DOC>
	<DOC>NCT00434096</DOC>
	<brief_summary>The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks. Secondary objectives are: - To evaluate the effect of SR141716 compared to placebo over a period of 52 weeks, on HDL-cholesterol and visceral fat area. - To evaluate the safety of SR141716 compared to placebo over a period of 104 weeks. - To evaluate the pharmacokinetics of SR141716.</brief_summary>
	<brief_title>Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Body Mass Index (BMI) &gt; 25 kg/m² Visceral Fat Area (VFA) &gt; 100 cm² Triglycerides (TG) &gt; 150 mg/dL and &lt; 700 mg/dL, and/or HDLcholesterol &lt; 40 mg/dL(Dyslipidemia) At least 1 criteria of the following 2 comorbidities: Impaired Glucose Tolerance or Type 2 diabetes Hypertension Patient with a secondary obesity. Patients who have received the diet therapy for less than 8 weeks before start of the observation period. Patients whose body weight changed by more than the variation of ± 2kg for screening period. Low compliance to drug intake (&lt; 80%) and dietary instruction during the observation period. Patients with type 1 diabetes. Patients with a primary hyperlipidemia (i.e., familial hypercholesterolemia, familial combined hyperlipidemia and familial type III hyperlipidemia). Patients with a LDLcholesterol &gt; 190 mg/dL at any of Weeks 8 or 4. Patients with a secondary hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Obesity disease</keyword>
	<keyword>cannabinoid-1 receptor</keyword>
</DOC>